Brind.

AbbVie's Humira is facing steep competition from Omvoh in the market.

1 report, 1 independent Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

AbbVie's Humira is facing steep competition from Omvoh in the market.

Who's involved

What this event is mainly about
AbbVieEli Lilly and Company

How it developed

Newest first. Tap a step to see who reported it.
  1. Declining sales of Humira due to biosimilar erosion.Sub-event
  2. AbbVie's Humira faces steep competition from Omvoh.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • ZacksEli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales Eli Lilly and Company LLY has gained tremendous market value in the past 2-3 years due to the success of its popular GLP-1 drugs, Mounja